LatestLicenses And Certifications 27 September 2026
Daiichi Sankyo and Merck Pull Lung Cancer Drug Application
Japanese pharmaceutical firm Daiichi Sankyo and U.S. giant Merck have voluntarily withdrawn their joint Biologics License Application for an accelerated approval of a lung cancer treatment, citing a strategic reassessment after recent trial data. The move halts the pending review in India and delays potential market entry, impacting investors and patients awaiting the therapy.
Key update
- Daiichi Sankyo and Merck have withdrawn their Biologics License Application for an accelerated lung cancer therapy.
- Decision follows a strategic review after mixed trial results, pausing the approval process in India.
For details, see the original article Investing.com.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.